NCT02027064 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Status UNKNOWN Phase PHASE4
NCT02024308 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Status UNKNOWN Phase PHASE4
NCT02016833 Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity Status COMPLETED Phase N/A
NCT02016729 A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia Status COMPLETED Phase PHASE1
NCT02014558 Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Status COMPLETED Phase PHASE1/PHASE2
NCT02007811 Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Status UNKNOWN Phase PHASE1/PHASE2
NCT01994837 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Status COMPLETED Phase PHASE2
NCT01961882 A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia Status COMPLETED Phase PHASE2
NCT01960387 Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Status TERMINATED Phase PHASE2
NCT01947322 Haploidentical NK-cell Infusion in Acute Myeloid Leukemia Status COMPLETED Phase PHASE1/PHASE2
NCT01943682 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Status COMPLETED Phase PHASE1
NCT01926587 Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Status COMPLETED Phase PHASE1/PHASE2
NCT01912274 Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Status COMPLETED Phase PHASE2
NCT01908387 Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms Status TERMINATED Phase PHASE1
NCT01889407 Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients Status UNKNOWN Phase N/A